Tier 4 — mechanistic

The betaine/GABA transporter and betaine: roles in brain, kidney, and liver

Stephen A Kempson, Yun Zhou, Niels C Danbolt
Frontiers in physiology 2014 5:159

Bibliography

PubMed
PMID 24795654
PubMed Central
PMC4006062
DOI
10.3389/fphys.2014.00159
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
Reported disclosure: statementThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Study snapshot

DesignNarrative review
ModelEvidence synthesis; mixed research models
SamplePublished literature; no newly enrolled participant cohort
InterventionReview of betaine-related evidence; no single assigned intervention
DurationEvidence review; source-specific study durations vary
EndpointsBetaine biology; Clinical and mechanistic evidence

What the study showed, in plain terms

Published in 2014, this source examined mechanistic and clinical reviews. Its evidence base was Published literature; no newly enrolled participant cohort. It evaluated Review of betaine-related evidence; no single assigned intervention across Evidence review; source-specific study durations vary.

Compares BGT1's well-characterized renal osmotic role with less certain liver and brain functions.

Transport and cell-culture mechanisms do not establish clinical efficacy; brain expression and relevance remain debated.

Continue with TMG Data Center

Continue with TMG and Liver Health: Human Trials Behind the Claims

Key findings

  • Compares BGT1's well-characterized renal osmotic role with less certain liver and brain functions.
  • The recorded outcome domains were Betaine biology; Clinical and mechanistic evidence.

What this study can and cannot tell us

  • Transport and cell-culture mechanisms do not establish clinical efficacy; brain expression and relevance remain debated.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Accessible full-text extract plus indexed bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 4
Betaine: A Promising Natural Product for Neurological and Psychiatric Diseases
Ying Zhang et al. · Current neuropharmacology · 2026
Tier 4
Association of trimethylamine oxide and its precursors with cognitive impairment: a systematic review and meta-analysis
Caiyi Long et al. · Frontiers in aging neuroscience · 2024
Tier 2
An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients
D Knopman et al. · Alzheimer disease and associated disorders · 2001
Tier 4
Global DNA hypomethylation and its correlation to the betaine level in peripheral blood of patients with schizophrenia
Yui Murata et al. · Progress in neuro-psychopharmacology & biological psychiatry · 2020
Tier 4
Decoding Betaine: A Critical Analysis of Therapeutic Potential Compared with Marketing Hype-A Narrative Review
Grzegorz Nikrandt et al. · The Journal of nutrition · 2024
Tier 4
Beneficial Effects of Betaine: A Comprehensive Review
Madan Kumar Arumugam et al. · Biology · 2021

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology